Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401512 | 1.00 | P2RX7 (0.46) | P2RX7S1PR1S1PR3KDM4EMEN1 | |
| SCHEMBL6405693 | 0.84 | P2RX7 (0.54) | P2RX7KDM4EALDH1A1 | |
| SCHEMBL6405690 | 0.84 | P2RX7 (0.54) | P2RX7KDM4EALDH1A1 | |
| SCHEMBL6405749 | 0.82 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL6408756 | 0.82 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL6403153 | 0.81 | P2RX7 (0.59) | P2RX7ALDH1A1 | |
| SCHEMBL6403150 | 0.81 | P2RX7 (0.59) | P2RX7ALDH1A1 | |
| SCHEMBL6401857 | 0.80 | P2RX7 (0.70) | P2RX7ALDH1A1 | |
| SCHEMBL6401859 | 0.80 | P2RX7 (0.70) | P2RX7ALDH1A1 | |
| SCHEMBL6405738 | 0.80 | P2RX7 (0.57) | P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | claimed |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2026-03-17 | — | — | US | disclosed |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2015-11-05 | — | — | US | disclosed |
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885S1PR1 513/4885S1PR3 509/4885 |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | KDM1A, KDM1B, KDM2A | P2RX7 4269/4885S1PR1 1820/4885S1PR3 2475/4885 |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK6, KDM1B, KDM6B | P2RX7 4348/4885S1PR1 1824/4885S1PR3 2448/4885 |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK3, CDKN1A, CDKL3 | P2RX7 4279/4885S1PR1 2884/4885S1PR3 2290/4885 |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | KDM1B, DOT1L, EZH2 | P2RX7 4403/4885S1PR1 1885/4885S1PR3 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.